Skip to main content

Table 1 Overview of the study design to evaluate the preventive efficacy of Bravecto® Plus spot-on solution at the minimum recommended dose (2.0 mg moxidectin/kg BW + 40 mg fluralaner/kg) compared to placebo treatment (0.9% saline solution)

From: Efficacy of Bravecto® Plus spot-on solution for cats (280 mg/ml fluralaner and 14 mg/ml moxidectin) for the prevention of aelurostrongylosis in experimentally infected cats

Group No. of cats Treatment (study day) Infection with 300 Aelurostrongylus abstrusus L3 (study day) Necropsy (study day)
1 8 0 Bravecto® Plus spot-on solution 84 131–134
28 Placebo
56 Placebo
2 8 0 Placebo
28 Bravecto® Plus spot-on solution
56 Placebo
3 7 0 Placebo
28 Placebo
56 Bravecto® Plus spot-on solution
4 8 0 Placebo
28 Placebo
56 Placebo